Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Avensia Grows B2B Offering and Customer Base

Modern commerce expert Avensia reports an increasing demand for the company’s services and solutions from the business-to-business (B2B) segment in 2021. As professional buyers increasly prefer to shop and interact with suppliers in digital channels the ROI for B2B digital transformation has never been so apparent.The Covid pandemic has accelerated the shift toward digital channels for B2B sellers and buyers. According to a survey featured in Digital Commerce 360, 80% of B2B buyers will do more purchasing online post pandemic and research from McKinsey shows that up to 80% of B2B decision

K-Fastigheter buys building right for more rental apartments in Gävle

K-Fast Holding AB has entered into an agreement with Alderholmen 4:34 Aktiebolag for the acquisition of the property Alderholmen 4:34 in the city of Gävle. The property has received a legally valid zoning plan enabling construction of about 110 apartments in the Group’s proprietary Lateral Low-Rise concept building, starting in 2022.K-Fast Holding AB (“K-Fastigheter”) has entered into an agreement to acquire the property Alderholmen 4:34 in central Gävle. K-Fastigheter estimates that gross floor area (GFA) amounts to approximately 7,200 square meters and that the Group can build

DanCann Pharma A/S: Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™

COPENHAGEN, Denmark, 30 November 2021, DanCann Pharma A/S ("DanCann Pharma"), a Danish company powered by cannabinoids, hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”), announce that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development – yesterday announced positive initial clinical data from its ongoing Phase 2 clinical trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for cancer pain. QIXLEEF™ is a botanical inhaled investigational new drug with a fixed ratio of THC and CBD that meets USA cGMP regulatory requirements.DanCann Pharma signed 05

EQT AB’s Nomination Committee for the Annual Shareholders’ Meeting 2022

EQT AB’s Nomination Committee for the Annual Shareholders’ Meeting 2022 has been appointed based on the ownership structure as of 31 August 2021.The Nomination Committee consists of                                                                    Jacob Wallenberg (Chairperson), appointed by Investor ABHarry Klagsbrun, appointed by Bark Partners ABHans Sterte, appointed by AlectaShireesh Vasupalli, appointed by Lennart BlecherConni Jonsson, Chairperson of the Board of EQT AB As of 31 August 2021, shareholders having appointed members to the Nomination Committee represented

Crunchfish publishes interim report for Q3 2021

Today, Crunchfish AB (“Crunchfish”) publishes its interim report for Q3 and the first nine months 2021. Below is a brief summary of the report.Group financials 2021-07-01 2020-07-01 2021-01-01 2020-01-01 2021-09-30 2020-09-30 2021-09-30 2020-09-30 Net sales (SEK) 1,055,973 2,970,495 3,073,760 7,248,878Profit or loss -7,293,098 -6,078,022 -23,688,767 -19,455,130before tax (SEK)Earnings per -0.26 -0.21 -0.84 -0.71share (SEK)Equity-assets 25.1% 85.3% 25.1% 85.3%-ratio (%)

Glaston writes off balance sheet items related to Heliotrope partnership, the write-off has no strategic importance

Glaston Corporation              Stock exchange release         30.11.2021 at 9.30Since late 2015, Glaston has been a small stockholder and development partner in a Californian start-up project with the goal to develop a nanotechnology based smart glass technology for the market. Glaston’s role in the project has been to develop a production line to produce smart glass developed by Heliotrope Technologies on an industrial scale. The development of the production line was completed already in 2018. Product development of the actual smart glass technology, on the other hand, has been delayed

KEBNI HAS RECEIVED AN ORDER FOR DRIVE AWAY ANTENNA SYSTEMS

KebNi AB (publ) receives an order for Drive Away Antenna Systems with a total value of 183 915 EUR (approx. 1,9 MSEK)Stockholm, 30 November 2021 - KebNi AB announces today that they have received an order for Satmission' s Drive-Away Antenna Systems. The order, with a total order value of 183 915 EUR (approx. 1,9 MSEK), is part of a previously announced framework agreement with a customer in Turkey.Om KebNi ABAbout KebNi AB (publ)KebNi has a long history and extensive experience in maritime and land-based satellite antenna solutions as well as solutions for inertial sensor systems

Biosergen publishes interim report for the third quarter 2021

Tuesday, November 30, 2021: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the third quarter 2021. The interim report is available as an attached document and on the company website (www.biosergen.net)Biosergen AB was registered in February 2021. On April 16, 2021, the company acquired Biosergen AS with the subsidiary Select Pharma PTY LTD and formed the group with Biosergen AB as parent company. As the company is new there are no comparative figures. Summary of the Interim Report for Q3 2021 Consolidated group revenue 2,709

Solid growth and accelerated investments as life at home is more important than ever

Ingka Group today reported total revenue of EUR 39.8 billion (EUR 37.4 billion FY20) in FY21 across its three business areas (IKEA Retail, Ingka Investments and Ingka Centres). Despite the challenges presented by the pandemic, the company has continued to accelerate investments in being more accessible, more affordable, and sustainable to better meet the changing needs and dreams of its customers.In another disruptive year, when IKEA stores had to close for even more days than in FY20, Ingka Group achieved a EUR 1.6 billion (EUR 1.2 billion FY20) net profit. Capital expenditure amounted

Read original

Immunovia’s CEO to step down during 2022

LUND, SWEDEN ― Immunovia AB (publ.) announced today that the Company’s President and Chief Executive Officer, Patrik Dahlen, has informed the Board of Directors of his intention to step down, for personal reasons. The search for a new CEO will start immediately. Although Patrik Dahlen will remain with the company for another six months to ensure an orderly transition, the Board would like to take this opportunity to express their gratitude already now for Patrik’s many contributions to the company.   Carl Borrebaeck, chairman of the Board of Directors, says:   “Immunovia’s

STENOCARE sign supply agreement with AgMedica Bioscience Inc

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“STENOCARE”) hereby announce that the company has signed a new agreement to source medical cannabis products from the Canadian company AgMedica Bioscience Inc (“AgMedica”). STENOCARE and AgMedica is already working with relevant health authorities to have their products made available for distribution.STENOCARE is a supplier of prescription-based medical cannabis products for patients’ treatment. The company has experience delivering prescription-based medical cannabis products for patients in Denmark

Lynparza granted FDA Priority Review for OlympiA

30 November 2021 07:00 GMT Lynparza granted Priority Review in the US forBRCA-mutated HER2-negative high-risk early breast cancer First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting AstraZeneca's supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Lynparza is being jointly developed and

Ericsson Mobility Report: Mobile data traffic increased almost 300-fold over 10 years

· Special ten-year edition of Ericsson Mobility Report highlights 5.5 billion additional smartphone users since 2011 · Mobile data traffic in Q3 2021 more than all mobile traffic generated up until the end of 2016 · 4.4 billion 5G subscriptions forecast for the end of 2027 – equaling around half of all mobile subscriptions at that timeEricsson (NASDAQ: ERIC) global insights reveal an almost 300-fold increase in mobile data traffic since 2011 – the year in which Ericsson Mobility Report was first published. The findings, based on current and historical network data, are included in the

Metso Outotec introduces modular Horizontal Mill Plant Units for simple grinding circuit selection and execution

Metso Outotec Corporation’s press release on November 30, 2021, at 09:00 a.m. EETMetso Outotec is launching yet another unique solution in its range of minerals processing plant islands: the Horizontal Mill Plant Units. The pre-engineered plant units provide optimized grinding performance and simplify project management through easy circuit selection and flowsheet implementation. At the same time, they ensure safe operability and maintainability thanks to their state-of-the-art design. The plant units feature Metso Outotec’s industry-leading technologies including grinding mills, slurry

Electrolux Professional shifts to green gases in refrigeration solutions

Electrolux Professional is replacing Hydrofluorocarbon greenhouse gases (HFC-gases), in 18 different product families, offering solutions with more natural, climate-friendly green gas alternatives.In May 2021, the first products using the most climate friendly CO\2\ natural refrigerant were launched on the market. The CO\2\ option is available for refrigerated cabinets, freezers, counters, Blast Chillers and several other refrigerated products. These greener, more natural refrigerant gas alternatives are safer and offer an improved operational performance, as well as increased energy

Proact delivers infrastructure for AI to Västra Götaland Region

The Västra Götaland Region in Sweden invests in its own AI platform to meet the growing needs of healthcare, culture, public transport and regional development. Proact has been selected as the supplier to the Västra Götaland Region (VGR) following a tender for AI and machine learning infrastructure.Proact's solution is based on technology from NetApp and Nvidia with the reference architecture Ontap AI. The combination of Proact specialists in AI infrastructure and the reference architecture makes it easier for VGR to get started and achieve faster results with AI and machine learning.

Valio focuses on solutions for health-conscious consumers at FIE/HIE Exhibition 2021 in Frankfurt

We are in the middle of a wellness revolution, and health-conscious consumers are here to stay. People of all ages are seeking food products that are not only more natural and healthier, but also improve the quality of their lives through high-quality nutrition. Rising trends, such as digestive wellness, sugar reduction, and quality protein are speeding up the growth of new product launches.Valio will showcase new possibilities to grow business with clean-label and better-for-you product concepts. And our sustainable nutrition solutions cover all life stages – from infants to ageing adults.

Stora Enso introduces portfolio for bio-based packaging foam

STORA ENSO OYJ PRESS RELEASE 30 November 2021 at 9:00 EETStora Enso is extending its packaging offering with a new portfolio of bio-based foams from wood. The products are fully recyclable and can be used for protective and thermal packaging. Lightweight wood foams address the need for climate-friendly, renewable and circular cushioning materials in inner packaging. Stora Enso’s offering consists of Fibrease™ by Stora Enso and Papira[® ]by Stora Enso. Both foams come with versatile technical and sustainability properties, and customers can select a suitable foam based on their specific

Ratos AB – change in number of shares and votes

The second opportunity to convert convertible debentures into shares according to the incentive program for the CEO and other key personnel in Ratos decided on by the 2018 Annual General Meeting was completed in November 2021. Through the conversion, the number of Class B shares increased by 40,000 and the number of votes by 4,000. After the increase, the share capital amounts to SEK 1,022,927,283.     Before the     After the conversion, no.  conversion,no.Class A 84,637,060   Class A shares: 84,637,060shares:Class B 240,061,760

Change in number of shares and votes in Volvo Cars

Press release 30 November 2021 In connection with the listing of Volvo Cars on Nasdaq Stockholm on 29 October 2021, extraordinary general meetings held on 17 October 2021 and 27 October 2021, respectively, resolved on directed issues of 479,524,179 common shares of class B in total. The new share issues have been registered with the Swedish Companies Registration Office during November 2021. In addition, during November 2021, 1,863,207,500 common shares of class A were converted to the corresponding number of common shares of class B.   As a result of the directed

Volvo Cars issues notice of early redemption of bonds

Press release 30 November 2021     Volvo Car AB today issues a notice of early redemption in respect of two of bonds, both guaranteed by Volvo Car Corporation: · SEK 2.5 billion Senior Floating Rate Note, due 7 March 2022 (XS1530953618) · SEK 0.5 billion 2.5% Senior Fixed Rate Note, due 7 March 2022 (XS1530953881) Volvo Cars AB hereby notifies the holders of the above-mentioned bonds that it intends to redeem them on 10 December 2021 at a price equal to 100 per cent of the principal amount, together with any accrued and unpaid interest. This is in

The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain

Sweden — 30 November 2021 — Camurus (NASDAQ STO: CAMX) today announces that the European Medicines Agency (EMA) has accepted the company’s submission of a Type II variation application for Buvidal[®] (buprenorphine) prolonged release injection to include treatment of chronic pain. “We are pleased that the review procedure has been initiated. There is a high unmet medical need in chronic pain, particularly among patients with concomitant opioid use problems. If approved, Buvidal could become an important therapeutic option for the management of chronic pain, adding to the current

Q4 2021 Year-end results burdened by the pandemic

"Demand and ticket sales are increasing, however, uncertainties continue to affect the ramp-up"August 2021–October 2021 · Revenue: MSEK 5,762 (3,035) · Income before tax (EBT): MSEK -945 (-3,252) · Income before tax and items affecting comparability: MSEK -911 (-3,024) · Net income for the period: MSEK -744 (-2,566) · Earnings per common share: SEK -0.12 (-4.44) SIGNIFICANT EVENTS DURING THE QUARTER · During the quarter, the number of passengers increased and more tickets were sold · Operations were scaled up to meet demand while more destinations opened up ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top